BRPI1013546A2 - usos de um inibidor da timidilato sintase e de uma terapia anticâncer - Google Patents
usos de um inibidor da timidilato sintase e de uma terapia anticâncerInfo
- Publication number
- BRPI1013546A2 BRPI1013546A2 BRPI1013546-4A BRPI1013546A BRPI1013546A2 BR PI1013546 A2 BRPI1013546 A2 BR PI1013546A2 BR PI1013546 A BRPI1013546 A BR PI1013546A BR PI1013546 A2 BRPI1013546 A2 BR PI1013546A2
- Authority
- BR
- Brazil
- Prior art keywords
- synthase inhibitor
- thymidylate synthase
- cancer
- therapy
- anticancer therapy
- Prior art date
Links
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 title abstract 3
- 239000003734 thymidylate synthase inhibitor Substances 0.000 title abstract 3
- 238000011319 anticancer therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 108010033040 Histones Proteins 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16921209P | 2009-04-14 | 2009-04-14 | |
| US16921609P | 2009-04-14 | 2009-04-14 | |
| US61/169212 | 2009-04-14 | ||
| US61/169216 | 2009-04-14 | ||
| US22516209P | 2009-07-13 | 2009-07-13 | |
| US61/225162 | 2009-07-13 | ||
| PCT/US2010/031112 WO2010120942A2 (en) | 2009-04-14 | 2010-04-14 | Histone modification patterns for clinical diagnosis and prognosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013546A2 true BRPI1013546A2 (pt) | 2019-04-09 |
Family
ID=42983132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013546-4A BRPI1013546A2 (pt) | 2009-04-14 | 2010-04-14 | usos de um inibidor da timidilato sintase e de uma terapia anticâncer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120094949A1 (enExample) |
| EP (1) | EP2419737A4 (enExample) |
| JP (1) | JP2012524278A (enExample) |
| CN (1) | CN102460173A (enExample) |
| AU (1) | AU2010236415A1 (enExample) |
| BR (1) | BRPI1013546A2 (enExample) |
| CA (1) | CA2758933A1 (enExample) |
| WO (1) | WO2010120942A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| PT2788767T (pt) | 2011-12-07 | 2017-12-06 | Belgian Volition Sprl | Método de detecção de adutos de nucleosoma |
| GB201303575D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
| GB201303576D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
| US20160355886A1 (en) * | 2013-12-30 | 2016-12-08 | Agency For Science, Technology And Research | Methods for measuring biomarkers in gastrointestinal cancer |
| JP2016044993A (ja) * | 2014-08-20 | 2016-04-04 | 有限会社マイテック | ヒストン化学修飾判定による癌診断方法 |
| SG10201903822XA (en) * | 2014-10-29 | 2019-05-30 | Belgian Volition Sprl | Method for the enrichment of circulating tumor dna |
| US10639349B2 (en) | 2015-04-06 | 2020-05-05 | The Johns Hopkins University | H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| CN108367995B (zh) * | 2015-10-06 | 2021-08-27 | 安大略省癌症研究所 | 靶向组蛋白途径以检测和克服蒽环类抗生素耐受性 |
| GB201612815D0 (en) * | 2016-07-25 | 2016-09-07 | Belgian Volition Sa | Novel combination test |
| US20190178894A1 (en) * | 2016-08-09 | 2019-06-13 | B.R.A.H.M.S Gmbh | Histones and/or proadm as markers indicating an adverse event |
| CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110221072B (zh) * | 2019-06-10 | 2022-08-02 | 东南大学 | 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用 |
| CN112904006B (zh) * | 2021-01-28 | 2022-12-27 | 中山大学 | 一种乳腺癌预后预测分子标志物及其应用 |
| WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
| WO2024233383A1 (en) * | 2023-05-05 | 2024-11-14 | University Of Utah Research Foundation | Systems and methods for point-of-care assessment based on pathology image analysis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| EP2267450B1 (en) * | 2005-04-29 | 2015-01-28 | The Regents of The University of California | Antibodies against histone modifications for clinical diagnosis and prognosis of cancer |
| US20080305962A1 (en) * | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
-
2010
- 2010-04-14 EP EP10765132A patent/EP2419737A4/en not_active Withdrawn
- 2010-04-14 CA CA2758933A patent/CA2758933A1/en not_active Abandoned
- 2010-04-14 WO PCT/US2010/031112 patent/WO2010120942A2/en not_active Ceased
- 2010-04-14 BR BRPI1013546-4A patent/BRPI1013546A2/pt not_active IP Right Cessation
- 2010-04-14 US US13/262,219 patent/US20120094949A1/en not_active Abandoned
- 2010-04-14 JP JP2012506186A patent/JP2012524278A/ja active Pending
- 2010-04-14 CN CN2010800251368A patent/CN102460173A/zh active Pending
- 2010-04-14 AU AU2010236415A patent/AU2010236415A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010120942A3 (en) | 2011-02-24 |
| CA2758933A1 (en) | 2010-10-21 |
| US20120094949A1 (en) | 2012-04-19 |
| JP2012524278A (ja) | 2012-10-11 |
| AU2010236415A1 (en) | 2011-12-01 |
| WO2010120942A2 (en) | 2010-10-21 |
| EP2419737A4 (en) | 2013-02-13 |
| CN102460173A (zh) | 2012-05-16 |
| EP2419737A2 (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013546A2 (pt) | usos de um inibidor da timidilato sintase e de uma terapia anticâncer | |
| Palumbo et al. | Autophagy and ionizing radiation in tumors: the “survive or not survive” dilemma | |
| CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
| Sun et al. | Red light-emitting diode irradiation regulates oxidative stress and inflammation through SPHK1/NF-κB activation in human keratinocytes | |
| EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
| BRPI0907637A8 (pt) | biomarcadores p53 | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
| WO2008018642A3 (en) | Genes and polypeptides relating to breast cancers | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| AR084831A1 (es) | Terapia anticancer mediante inhibidores de quinasa | |
| BR122019016628B8 (pt) | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular | |
| BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
| ECSP088782A (es) | Compuestos nuevos | |
| WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
| BR112012009262A2 (pt) | ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo | |
| WO2008005281A3 (en) | Genes associated with chemotherapy response and uses thereof | |
| WO2008073629A3 (en) | Bifunctional predictors of cancer treatment sensitivity and resistance | |
| BR112015007144A2 (pt) | uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores | |
| WO2011133609A3 (en) | Methods and kits to predict therapeutic outcome of btk inhibitors | |
| EP4524569A3 (en) | Methods, compositions and devices for treating cancer with illudofulvenes | |
| NO20074065L (no) | Farmakogenomiske markorer for prognose av faste tumorer | |
| BR112015012507A8 (pt) | método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase | |
| WO2015073896A3 (en) | Biomarkers for psma targeted therapy for prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |